Article: Prostate cancer vaccine

Thread view:

Enable EMail Alerts

Start New Thread

Thread rating:

David S. - 14 Mar 2005 13:35 GMT

http://www.businessweek.com/ap/financialnews/D88K8NHO0.htm?campaign_id=apn_home_down

Reply to this Message

Bill - 14 Mar 2005 16:35 GMT

This is another dendritic cell vaacine that showed amazing results in
its Phase II trials at Duke. Get this - PSADT increased from 3 mos. to
100 mos.! That's practically a cure.

However, the bitter irony of all these trials and encouraging drugs is
that they are almost exclusively for advanced, hormone refractory if
not metastatic PCa. There is nothing for early recurrent disease. But,
hopefully, they will have developed them for general use by the time I
get to that point.

Bill Denton
RP 2/12/02
PSA .45
Memphis

Reply to this Message

I. P. Freely - 14 Mar 2005 19:34 GMT

Unless, of course, it simply suppresses the PSA, not the cancer, as so many
meds do.

I.P.

> This is another dendritic cell vaacine that showed amazing results in
> its Phase II trials at Duke. Get this - PSADT increased from 3 mos. to
[quoted text clipped - 5 lines]
> hopefully, they will have developed them for general use by the time I
> get to that point.

Reply to this Message

Steve Kramer - 14 Mar 2005 19:56 GMT

In reading the article, that is not the case. However, it is just an
article.

Signature

PSA 16 10/17/2000 @ 46
Biopsy 11/01/2000 G7 (3+4), T2c
RRP 12/15/2000 G7 (3+4), T3bN0M0
Seminal Vesicle involvement, Neg margins
PSA .1 .1 .1 .27 .37 .75
EBRT 05-07/2002 @ 47
PSA .34 .22 .15 .21 .32
Lupron 07/03 (1 mo) 8/03 (4 mo), 12/03, 4/04, 09/04, 01/05
PSA .07 .05 .06 .05

non Illegitimi carborundum

> Unless, of course, it simply suppresses the PSA, not the cancer, as so many
> meds do.
[quoted text clipped - 10 lines]
> > hopefully, they will have developed them for general use by the time I
> > get to that point.

Reply to this Message

Mike - 15 Mar 2005 09:38 GMT

Of course, I have seen this all before:

This news release may contain forward-looking statements made pursuant to the
“safe harbor” provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that such forward-looking statements in this press
release regarding potential applications of Geron’s technology constitute
forward-looking statements that involve risks and uncertainties, including,
without limitation, risks inherent in the development and commercialization of
potential products, need for future capital and maintenance of our intellectual
property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional information on
potential factors that could affect our results and other risks and
uncertainties are detailed from time to time in Geron’s periodic reports,
including the annual report on Form 10-K for the year ended December 31, 2004.

Mike

> In reading the article, that is not the case. However, it is just an
> article.

Reply to this Message

gourd_dancer - 15 Mar 2005 01:03 GMT

What it does according to my Research Medical Oncologist is simply change
certain genes to kill the cancer. As I have reported before, anyway they
slice and diced prostate cancer the tumor is dead. The cancer cells do not
go away, they simply die. I am interested immensely because I will be
eligible for a Phase II test in December 2005 at Methodist Research Center,
formerly Baylor College of Medicine. Ah divorces are nasty..........

Reply to this Message

Steve Kramer - 14 Mar 2005 19:55 GMT

I'm all for knocking down the refractory and metsatic PCa before moving on.
Of course, a couple of years ago, I might have thunk differently.

Signature

> This is another dendritic cell vaacine that showed amazing results in
> its Phase II trials at Duke. Get this - PSADT increased from 3 mos. to
[quoted text clipped - 10 lines]
> PSA .45
> Memphis

Reply to this Message